Patent application number | Description | Published |
20080300286 | Tyrosine Derivatives Substituted By N-Arylacryloyl as Agonists of Hppar Alpha and/or Hppar Gamma - The present invention relates to a compound of formula I, racemates, optically active isomers, or pharmaceutically acceptable salts or solvates thereof, and a pharmaceutical composition comprising the compound, the various radicals in the formula I are the same as defined in the claims. The present invention also relates to a process for preparing the compound of formula I and use of said compound in the preparation of a medicament for the treatment of hyperglycemia, dyslipidemia, type II diabetes mellitus including associated diabetic dyslipidemia | 12-04-2008 |
20090176877 | OSELTAMIVIR PHOSHATE GRANULE AND PREPARATION METHOD THEREOF - The present invention relates to an oseltamivir phosphate granule and preparation method thereof. The said granule comprises 1.97-19.8 wt. % oseltamivir phosphate, 75.0-97.5 wt. % diluent, 0.1-5.0 wt. % binder, optionally 1.0-5.0 wt. % edible flavouring essence, sweetener and/or edible pigment. It is prepared by using 30-55 v/v % aqueous ethanol solution as moistening agent. The granules prepared by the formulation and method according to the present invention have good uniformity and stability and are water-soluble. The administration dosage of the granules can be conveniently selected based on the age and body weight of patients. The oseltamivir phosphate granule is suitable for administering to old people, children and flu gravis patients and those patients that swallow inconveniently or difficulty. The preparation of the granule is simple and low in production cost. | 07-09-2009 |
20100004268 | Optically Pure Dihydropyrimidine Compounds and Their Uses for the Preparation of a Medicament for Treatment and Prevention of Viral Diseases - The present invention relates to an optically pure compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof, a process for preparing the optically pure compound of formula (I), and use of the optically pure compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof as a medicament, in particular as a medicament for the treatment and prevention of type B hepatitis. | 01-07-2010 |
20100087448 | Dihydropyrimidine Compounds and Their Uses in Preparation of Medicaments for Treating and Preventing Antiviral Diseases - The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof, to a process for preparing the compound of formula (I), and to use of the compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof as a medicament, in particular as a medicament for the treatment and prevention of type B hepatitis. | 04-08-2010 |
20110009427 | ARYL PYRIMIDINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF - The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof. Various substituents in the formula (I) are as defined in the specification. The present invention also relates to a pharmaceutical composition comprising the compound of formula (I), the preparation method of compound of formula (I), and the use of the compound for the preparation of a medicament for treating and/or preventing human peroxisome proliferators activated receptor δ (hPPARδ)-associated diseases and risk factors. | 01-13-2011 |
20110065795 | (1S,2S,3S,4R)-3-[(1S)-1-ACETYLAMINO-2-ETHYL-BUTYL]-4-UANIDINO-2-HYDROXYL-C- YCLOPENTYL-1-CARBOXYLIC ACID HYDRATES PHARMACEUTICAL USES THEREOF - The present invention relates to (1S,2S,3S,4R)-3-[(1S)-1-acetylamino-2-ethyl-butyl]-4-guanidino-2-hydroxy-cyclopentyl-1-carboxylic acid hydrates compounds, preparing methods thereof, pharmaceutical compositions containing said compounds and preparing methods thereof, and the clinical uses of said compounds as neuramidinase inhibitors for anti-influenza. | 03-17-2011 |
20110178141 | Thiazoliums and Their Use for Treating Protein Aging Associated Diseases - The present invention relates to a composition of a thiazolium compound of formula I or a solvate thereof, wherein the definitions of groups in the formula I are as those given in the claims: | 07-21-2011 |
20120122914 | Sustained-release composition containing tetrahydropyrido[4,3-b]indole derivatives and preparation of the derivatives - The present invention relates to a sustained-release composition containing 2,3,4,5-tetrahydro-2,8-dimethyl-5-[2-(6-methyl-3-pyridyl)ethyl]-1H-pyrido[4,3-b]indole or a pharmaceutically acceptable salt thereof as an active ingredient, preparation thereof and the compound. The composition is suitable for oral administration by one time per day, and achieves the peak plasma concentration at 1.0 to 3 hours after oral administration. The composition is suitable for manufacturing a medicament for treatment of cognitive dysfunction syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, or senile dementia. | 05-17-2012 |
20120149695 | DIHYDROPYRIMIDINE COMPOUNDS AND PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF - Disclosed are dihydropyrimidine compounds and preparation methods, pharmaceutical compositions and uses thereof. Specifically, the compounds described herein in general formula (I), or their isomers, pharmaceutically acceptable salts or hydrates are provided, wherein each variable has the meaning as defined in the description. Also provided are a process for preparing the compounds of the general formula (I), the use of the compounds, an isomer thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof as a medicament, in particular as a medicament for the treatment and/or prevention of Hepatitis B. | 06-14-2012 |
20130085183 | AROMATIC BUTAN-2-OL COMPOUNDS AND PREPARATION AND USES THEREOF - Aromatic butan-2-ol compounds, preparation methods for making the compounds, and uses of the compounds are provided. Specifically, the compound of Formula I, or an optical isomer, racemate, diastereomer, pharmaceutically acceptable salt, or solvate thereof, is provided, where each of the substituents is defined. In addition, a pharmaceutical composition containing the compound, and the use of the compound in manufacture of a medicament for the treatment and/or prophylaxis of a disease or disorder caused by | 04-04-2013 |
20130190319 | PYRIDAZINE DERIVATIVES AND USE THEREOF AS MEDICAMENTS FOR TREATING MICRORNA VIRAL INFECTION - Disclosed are pyridazine derivatives represented by Formula I or pharmaceutically acceptable salts or hydrates thereof, pharmaceutical compositions comprising the compounds, methods of treating and/or preventing diseases or disorders associated with viral infections in patients using the compounds, and the use of the compounds in preparing the medicaments for treating and/or preventing diseases or disorders associated with viral infections. The compounds represented by Formula I have antiviral activity, especially anti-microRNA viral activity. Symbols in the compounds represented are described in the specification. | 07-25-2013 |
20130331604 | (1S,2S,3S,4R)-3-[(1S)-1-acetylamino-2-ethyl-butyl)-4-guanidino-2-hydroxy-c- yclopentyl-1-carboxylic acid hydrates pharmaceutical uses thereof - The present invention relates to (1S,2S,3S,4R)-3-[(1S)-1-acetylamino-2-ethyl-butyl]-4-guanidino-2-hydroxy-cyclopentyl-1-carboxylic acid hydrates compounds, preparing methods thereof, pharmaceutical compositions containing said compounds and preparing methods thereof, and the clinical uses of said compounds as neuramidinase inhibitors for anti-influenza. | 12-12-2013 |
20140080840 | Thiazolamine Derivative and Use Thereof as Anti-Picornaviral Infection Medicament - Disclosed is as a substituted thiazolamine derivative represented by Formula I or a pharmaceutically acceptable salt thereof or a hydrate thereof (the definitions of each group in the formula are as presented in the description), and the application thereof in the prevention and/or treatment of viral diseases induced by picornavirus. Also disclosed is a pharmaceutical composition containing the compound. | 03-20-2014 |